Nutriband Inc. (NASDAQ: NTRB) CEO Gareth Sheridan has published a letter to shareholders outlining the company's key achievements in 2025 and its priorities for 2026. The update emphasizes Nutriband's focus on creating shareholder value through disciplined capital management, including a 25% preferred stock dividend issued in 2025, and efforts to reduce share price volatility as IPO-era warrants are set to expire in October 2026.
The company reported significant progress on its lead product, AVERSA™ Fentanyl, an abuse-deterrent opioid transdermal patch under development. During 2025, Nutriband strengthened its intellectual property portfolio with new U.S. patent issuances, completed commercial manufacturing scale-up, and received feedback from the U.S. Food and Drug Administration (FDA) through a Type C meeting to support its regulatory pathway. The company's AVERSA™ technology is designed to be incorporated into transdermal patches to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
Additional 2025 milestones included Nutriband's inclusion in four Russell indexes and the execution of strategic transactions intended to support long-term growth as the company advances AVERSA™ Fentanyl toward commercialization. The company's corporate website is www.nutriband.com.
This news is important because it provides investors and stakeholders with a clear view of Nutriband's operational and financial trajectory. The progress on AVERSA™ Fentanyl addresses a critical public health issue: the opioid crisis. Abuse-deterrent formulations are a key component in combating prescription drug misuse, which remains a significant societal challenge. The FDA's engagement through the Type C meeting indicates regulatory dialogue is active, a positive step for the product's development timeline.
The implications of this announcement extend to the pharmaceutical industry, healthcare providers, and patients. A successful abuse-deterrent opioid patch could offer a safer pain management option, potentially reducing incidents of misuse and overdose. For the industry, it represents innovation in drug delivery and safety technology. For investors, the outlined milestones and financial management, including the dividend and focus on reducing volatility, signal a company maturing from development toward potential commercialization. The full details of the shareholder letter are available via the press release at https://nnw.fm/kjl5j.
